Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide for COVID-19 pneumonia
ChiCTR2000030058Phase 3Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of leflunomide in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Days from positive to negative viral nucleic acid test. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
leflunomide
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on ChiCTR2000030058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030058.